A new trading day began on Friday, with Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) stock price down -8.71% from the previous day of trading, before settling in for the closing price of $3.10. ZNTL’s price has ranged from $2.83 to $18.24 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -20.00%. Meanwhile, its annual earnings per share averaged 32.96%. With a float of $61.39 million, this company’s outstanding shares have now reached $70.77 million.
Let’s determine the extent of company efficiency that accounts for 168 employees. In terms of profitability, gross margin is 96.87%, operating margin of -516.95%, and the pretax margin is -455.68%.
Zentalis Pharmaceuticals Inc (ZNTL) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Zentalis Pharmaceuticals Inc is 13.67%, while institutional ownership is 97.56%. The most recent insider transaction that took place on Oct 04 ’24, was worth 5,098. In this transaction Principal Accounting Officer of this company sold 1,603 shares at a rate of $3.18, taking the stock ownership to the 33,855 shares. Before that another transaction happened on May 31 ’24, when Company’s President, Interim CFO sold 9,597 for $11.98, making the entire transaction worth $114,972. This insider now owns 633,680 shares in total.
Zentalis Pharmaceuticals Inc (ZNTL) Recent Fiscal highlights
In its latest quarterly report, released on 6/30/2024, the company reported earnings of -0.79 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.97 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 32.96% per share during the next fiscal year.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Trading Performance Indicators
Here are Zentalis Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 6.59. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.96.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.75, a number that is poised to hit -0.91 in the next quarter and is forecasted to reach -3.57 in one year’s time.
Technical Analysis of Zentalis Pharmaceuticals Inc (ZNTL)
Looking closely at Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL), its last 5-days average volume was 1.06 million, which is a drop from its year-to-date volume of 1.3 million. As of the previous 9 days, the stock’s Stochastic %D was 43.95%. Additionally, its Average True Range was 0.24.
During the past 100 days, Zentalis Pharmaceuticals Inc’s (ZNTL) raw stochastic average was set at 0.11%, which indicates a significant decrease from 1.75% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 61.54% in the past 14 days, which was lower than the 145.37% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.33, while its 200-day Moving Average is $8.62. However, in the short run, Zentalis Pharmaceuticals Inc’s stock first resistance to watch stands at $3.01. Second resistance stands at $3.20. The third major resistance level sits at $3.29. If the price goes on to break the first support level at $2.73, it is likely to go to the next support level at $2.64. Now, if the price goes above the second support level, the third support stands at $2.45.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Key Stats
With a market capitalization of 201.24 million, the company has a total of 71,026K Shares Outstanding. Currently, annual sales are 0 K while annual income is -292,190 K. The company’s previous quarter sales were 40,560 K while its latest quarter income was 10,070 K.
